Yishake Mumingjiang, Yasen Miersalijiang, Jiang Libo, Liu Wangmi, Xing Rong, Chen Qian, Lin Hong, Dong Jian
Department of Orthopedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
J Orthop Res. 2018 Mar;36(3):937-944. doi: 10.1002/jor.23682. Epub 2018 Jan 16.
There has been no study regarding the effect of a combination of teriparatide (TPTD) and zoledronic acid (ZA) on vertebral fusion. In this study, we investigate the effect of single and combined TPTD and ZA treatment on lumbar vertebral fusion in aged ovariectomized (OVX) rats. Sixty two-month-old female Sprague-Dawley rats were ovariectomized and underwent bilateral L4-L5 posterolateral intertransverse fusion after 10 months. The OVX rats received vehicle (control) treatment, or ZA (100 µg/kg, once), or TPTD (60 µg/kg/2 d for 42 d), or ZA + TPTD until they were euthanized at 6 weeks following lumbar vertebral fusion. The lumbar spine was harvested. Bone mineral density (BMD), bone fusion, bone volume (BV), and bone formation rate (BFR)were analyzed by dual-energy X-ray absorptiometry (DXA), radiography, micro-computed tomography, and histomorphometry. Compared with vehicle (control) treatment, ZA and TPTD monotherapy increased bone volume (BV) at fusion site, and ZA + TPTD combined therapy had an additive effect. Treatment with TPTD and ZA + TPTD increased the bone fusion rate when compared with the control group. ZA monotherapy did not alter the rate of bone fusion. The TPTD and ZA + TPTD treatment groups had increased mineral apposition rate (MAR), mineralizing surfaces/bone surface ((MS/BS), and BFR/BS compared with the OVX group. Our experiment confirm that the monotherapy with TPTD and combination therapy with ZA + TPTD in an OVX rat model of osteopenia following lumbar vertebral fusion surgery increased bone fusion mass and bone fusion rate, and ZA + TPTD combined therapy had an additive effect on bone fusion mass. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:937-944, 2018.
关于特立帕肽（TPTD）和唑来膦酸（ZA）联合使用对椎体融合的影响尚无研究。在本研究中，我们调查了单独使用及联合使用TPTD和ZA治疗对老年去卵巢（OVX）大鼠腰椎融合的影响。60只2月龄雌性Sprague-Dawley大鼠接受去卵巢手术，并在10个月后进行双侧L4-L5后外侧横突间融合术。OVX大鼠接受溶剂（对照）治疗、或ZA（100μg/kg，单次）、或TPTD（60μg/kg/2天，共42天）、或ZA + TPTD治疗，直至在腰椎融合术后6周实施安乐死。采集腰椎。通过双能X线吸收法（DXA）、X线摄影、显微计算机断层扫描和组织形态计量学分析骨密度（BMD）、骨融合、骨体积（BV）和骨形成率（BFR）。与溶剂（对照）治疗相比，ZA和TPTD单一疗法增加了融合部位的骨体积（BV），且ZA + TPTD联合疗法具有相加作用。与对照组相比，TPTD和ZA + TPTD治疗可提高骨融合率。ZA单一疗法未改变骨融合率。与OVX组相比，TPTD和ZA + TPTD治疗组的矿物质沉积率（MAR）、矿化表面/骨表面（（MS/BS））和BFR/BS增加。我们的实验证实，在腰椎融合手术后的OVX骨质疏松大鼠模型中，TPTD单一疗法以及ZA + TPTD联合疗法可增加骨融合量和骨融合率，且ZA + TPTD联合疗法对骨融合量具有相加作用。©2017骨科学研究协会。由Wiley Periodicals, Inc.出版。《矫形外科学研究》36:937 - 944, 2018。
